Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$167.36 USD
+0.20 (0.12%)
Updated Sep 4, 2024 04:00 PM ET
Pre-Market: $167.05 -0.31 (-0.19%) 8:30 AM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$167.36 USD
+0.20 (0.12%)
Updated Sep 4, 2024 04:00 PM ET
Pre-Market: $167.05 -0.31 (-0.19%) 8:30 AM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Zacks News
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Invesco S&P 500 Quality ETF (SPHQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHQ
Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) concluded the recent trading session at $167.16, signifying a +0.78% move from its prior day's close.
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
by Kinjel Shah
LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
by Zacks Equity Research
Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
by Zacks Equity Research
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
Addex Stock Soars on Crucial Update From Indivior Research Deal
by Zacks Equity Research
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $162.95, moving -1.01% from the previous trading session.
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
by Zacks Equity Research
MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
by Zacks Equity Research
The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.
Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
by Kinjel Shah
LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $161.43, denoting a +0.79% change from the preceding trading day.
J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
by Zacks Equity Research
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition
by Zacks Equity Research
Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Why Is Johnson & Johnson (JNJ) Up 2.4% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medicare Releases Negotiated Prices on 10 Expensive Drugs
by Sundeep Ganoria
Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.